Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New Brunswick Scientific and Pall Corporation have signed a joint product development and marketing agreement to create and supply new disposable bioreactor systems.
Subscribe to our email newsletter
With a motto to serve upstream applications from process development laboratory to the full-scale cGMP production suite, their joint attempt is expected to build on the capabilities of Pall’s Allegro single-use biocontainer platform and New Brunswick’s CelliGen bioprocess controller.
The recent partnership combines the expertise of both the entities in upstream biopharmaceutical processing. New Brunswick Scientific’s CelliGen BLU Single-Use Stirred-Tank Bioreactor, and Pall’s MicroReactor Technologies and Micro-24 microbioreactor will play a key role in the agreement.
Mike Sattan, vice president of marketing at New Brunswick, said: “This is an exciting step forward, as the new system will enable us to offer an even broader range of bioreactor technology options, while we continue to provide a control system with the reliability, ease of use and configurability that our customers have come to expect.”
Ken Frank, president of Pall Life Sciences Biopharmaceuticals, said: “We are delighted to be able to partner with New Brunswick to extend our Allegro single-use technology to cover the entire range of upstream bioprocessing applications.
“We believe these new bioreactor systems will provide our customers with greater benefits in operational simplicity, product quality assurance, and process economics.”